Efficacy of CA330 hemoadsorption combined with CRRT in sepsis-associated acute kidney injury: A retrospective cohort study
Abstract
Hemoadsorption regulates sepsis-related inflammatory mediators. The CA330 cartridge, a cross-linked divinylbenzene/polyvinylpyrrolidone (DVB/PVP) adsorbent, is approved in China but no prospective or retrospective clinical studies have validated the efficacy of the CA330 in the context of sepsis-associated acute kidney injury (SA-AKI). This single-center retrospective study (January 2022-December 2024) enrolled 60 SA-AKI patients (SEPSIS-3 criteria, AKI stage II): 30 received CA330 + continuous renal replacement therapy (CRRT), 30 CRRT alone. Key outcomes included hemodynamics, interleukin-6 (IL-6) levels, renal recovery, and mortality. The CA330 group had higher baseline severity (APACHE II score, norepinephrine (NE) requirements, IL-6). After 24h, it showed 60.2% lower NE (P
Fields of Study & Subjects
Acute Kidney Injury Research
Trauma
Hemostasis
Coagulopathy
Resuscitation
Immune Response and Inflammation
Publication details
- Journal / source
- Medicine
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 105
- Issue
- 5
- Pages
- e47487–e47487
- Publication date
- 30 January 2026
- Language
- EN